April 08, 2026

Small Phase II Study Examines Triplet Regimen for Patients With HER2-Positive Breast Cancer and Leptomeningeal Metastasis

Results from a small phase II study suggest that a triplet regimen may improve symptoms and extend survival in some patients with breast cancer and leptomeningeal metastasis, who often face limited tr...

The ASCO Post

April 07, 2026

Can ctDNA Negativity Predict Metastasis-Free Survival in Muscle-Invasive Bladder Cancer?

Circulating tumor DNA (ctDNA) may be used to predict metastatic risk and identify which patients with muscle-invasive bladder cancer are more likely to benefit from a bladder-sparing treatment approac...

The ASCO Post

April 07, 2026

Timely Scans May Reduce Mortality in Patients Who Present to the ER With Hematuria

One in 10 patients who present to the emergency room (ER) with visible hematuria die within 3 months, new research from the United Kingdom has indicated. The WASHOUT study found that a scan administer...

The ASCO Post

April 06, 2026

Fullerene Cream vs Trolamine Cream in Reducing Acute Radiation Dermatitis From Radiation Therapy for Head and Neck Cancer

In a single-center Chinese phase II trial reported in the Journal of Clinical Oncology, Liu et al found that fullerene cream was better than trolamine cream in reducing risk for acute radiation dermat...

The ASCO Post

April 03, 2026

FDA Grants Traditional Approval to Brexucabtagene Autoleucel for Relapsed or Refractory MCL

The CAR T-cell therapy brexucabtagene autoleucel (Tecartus) was issued full approval for adult patients with relapsed or refractory mantle cell lymphoma (MCL). The approval now includes efficacy, safe...

The ASCO Post

April 03, 2026

HER2CLIMB-05 Study: Tucatinib Enhances Progression-Free Survival as First-Line Maintenance for HER2-Positive Metastatic Breast Cancer

The addition of the selective HER2 inhibitor tucatinib to trastuzumab and pertuzumab as first-line maintenance therapy significantly prolonged investigator-assessed progression-free survival in patien...

The ASCO Post

April 01, 2026

Activity Observed With Novel KRAS Inhibitor in Pancreatic Cancer

A novel KRAS G12D inhibitor produced disease control in almost 80% of patients with heavily pretreated advanced or metastatic KRAS G12D–mutated pancreatic cancer in an early-phase study reported at th...

The ASCO Post

March 30, 2026

New Frontiers in Neuroendocrine Tumors: Enhancing Diagnosis, Treatment, and Patient Outcomes

Explore the latest advancements in diagnosing and treating neuroendocrine tumors as discussed by Paula S. Kennedy-Newton at JADPRO Live 2025.

JADPRO

March 30, 2026

Radiotherapy May Reduce Risk of Lymphedema in Patients With Breast Cancer More Effectively Than Surgery

These results come from the pilot phase of the phase III ADARNAT randomized international clinical trial, which is investigating whether axillary radiotherapy has a lower risk of lymphedema than axill...

The ASCO Post

March 30, 2026

Therapeutic Advances in Metastatic Melanoma: TILs, ImmTACs, and Targeted Therapies

Explore the latest advances in metastatic melanoma treatment from leading experts at Mass General Hospital.

JADPRO